MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis - Wikidata - awgldk - TriplyDB

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

http://www.wikidata.org/entity/Q34047897

about

Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation.Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Current Challenges in Stem Cell Transplantation in Myelofibrosis.Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms.Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning.The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury.P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.Novel Therapies for Myelofibrosis.Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis.Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.

P2860

Q26786893-2F44A5B9-ABE4-4BDA-ABA0-3EF09BCB6A18 Q37272164-EFAD4F37-7C5D-4FB9-B3BD-9DAA6087ABEB Q37506624-7DA12BDA-BB45-4870-9215-A633CEE55D61 Q38349213-1EB7CC84-1752-4C4E-9323-F54FF66B55B5 Q38569146-F33B8172-C332-4E5A-84B2-C13B192D869C Q38570614-309C7919-6DF6-454B-9B1D-CE8EB790AF7C Q38603384-4BBF5CE7-2DA3-4324-A037-6F882F7EA622 Q38667263-D29560F4-2CEC-4080-9285-DA9BE8D8D8F3 Q39357992-5DBAD253-65F3-47E8-A7CC-2A597A5FF8AE Q40261233-C1DF370E-42A0-4171-9168-5A23A6A35D7D Q41519713-0232DEE5-75CD-4A4D-8A57-ED3E0EE6573F Q41621459-4E4E7B2B-60E7-4845-AB93-B27F198B6C41 Q42794052-51906809-FD9B-4A3D-976F-4E9FC0BC21AA Q49419358-3F44BACE-8705-4A39-BBAE-A3F6FEDA7334 Q49442070-54086893-E95E-497B-8699-2AF7279403C3 Q52641887-9551E5CF-BAE4-499A-8263-A61DED247121 Q52664220-79C573E6-4C07-4934-B15E-27943F8E5558 Q52817185-3CA6E8D7-B8CF-43DF-85DE-4842F8CCE34D Q54256608-A20F842C-DAAF-435B-B5D5-B4E90E7A408D Q55060741-3233FE5D-5C7B-4C85-B2C3-DCC69290D401

P2860

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

http://www.wikidata.org/entity/Q34047897

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

MPD-RC 101 prospective study o ...... in patients with myelofibrosis

@ast

MPD-RC 101 prospective study o ...... in patients with myelofibrosis

@en

MPD-RC 101 prospective study o ...... in patients with myelofibrosis

@nl

type

label

MPD-RC 101 prospective study o ...... in patients with myelofibrosis

@ast

MPD-RC 101 prospective study o ...... in patients with myelofibrosis

@en

MPD-RC 101 prospective study o ...... in patients with myelofibrosis

@nl

prefLabel

MPD-RC 101 prospective study o ...... in patients with myelofibrosis

@ast

MPD-RC 101 prospective study o ...... in patients with myelofibrosis

@en

MPD-RC 101 prospective study o ...... in patients with myelofibrosis

@nl

P1433

Q34047897-6131B0A2-BA9D-4B5B-B7EC-61C5C2637686

P1476

Q34047897-36EC81E5-D3EC-436E-B12F-6D8916BB5655

P2093

Q34047897-008E9C15-D458-41C0-B74E-AFED4070DF48

Q34047897-0D0E44CE-9A4A-4013-B755-1FAFADF9FA9F

Q34047897-1689AC97-1816-43A2-9BC6-50270F941B7A

Q34047897-2F8EA416-1E6A-44D3-9906-4E2CE700A0C9

Q34047897-3281C990-8F69-49E2-9037-F72D994B6E4C

Q34047897-463B0A6C-E11C-47C4-AE05-2A05E85D8AAB

Q34047897-47FC7DAE-0F54-4842-8077-50626D27BB21

Q34047897-482F38FF-B598-43D2-9BF6-0DCCE20AFE39

Q34047897-4FD92A28-E8EC-4BA3-8943-4ABF41663962

Q34047897-53E1F1A2-808A-414A-A766-6159B32215DB

P2860

Q34047897-0207DD59-B9CB-4C8F-9F93-F8D521EAA929

Q34047897-0423D26C-BAA9-49FF-9E31-0BFDCCE15FFF

Q34047897-042E41CD-8A04-410F-9B71-815A318BE891

Q34047897-052F4948-302F-4706-AF81-4B70260023F4

Q34047897-0C9499E7-FCCA-424D-B2EA-AC953C471C24

Q34047897-1028045C-D925-42A5-A66B-ACDE4880968E

Q34047897-10DB3C06-2785-4E1A-8673-68FABAA07F22

Q34047897-16856C49-004F-40A0-AFA0-5665BB99FA3E

Q34047897-1A75F179-87F9-4420-83E3-C7143627D6CA

Q34047897-24941EA5-2A4F-42DF-9206-E84AC41FE31F

P304

Q34047897-C313BA26-DF53-425D-8374-63BD992DC76F

P31

Q34047897-0726D9E8-F355-41E1-A18B-43AEBD318643

P356

Q34047897-55FB4401-190C-43B5-A04D-7B232A882B59

P407

Q34047897-17051FA0-6060-4ED1-9F8B-7563944C9006

P433

Q34047897-885EBFD4-4AD7-4AB1-B2A3-472714C50D80

P478

Q34047897-03E8A58C-C194-4570-A807-CB4C3930A5B3

P50

Q34047897-08293986-9805-4454-9F1C-F35F43C339D0

Q34047897-1F11C70C-C9BA-422E-8B58-D9F5848B672F

Q34047897-30AD07A9-7591-4192-8749-C27BB836D161

Q34047897-3212FCCD-EF47-4CF5-903A-F5AFF3F932A9

Q34047897-6520B62D-32CF-4CB8-A358-A048A45ACB59

P577

Q34047897-7402A230-2902-49D4-A9DD-EBF07F2FC515

P5875

Q34047897-7E568439-64D4-483E-A0EC-A1B040D66BB7

P698

Q34047897-D3FB3E12-3070-4EEA-87EF-4E8D5FB73F72

P932

Q34047897-3D208111-20E4-4CAF-A386-202B571F39FB

P356

BLOOD-2014-04-572545

P1433

P1476

MPD-RC 101 prospective study o ...... in patients with myelofibrosis

@en

P2093

Alessandro M Vannucchi

http://www.w3.org/2001/XMLSchema#string

Alessandro Rambaldi

http://www.w3.org/2001/XMLSchema#string

Andrea Bacigalupo

http://www.w3.org/2001/XMLSchema#string

Attilio Orazi

http://www.w3.org/2001/XMLSchema#string

Bjorn Andreasson

http://www.w3.org/2001/XMLSchema#string

Crystal Miller

http://www.w3.org/2001/XMLSchema#string

Giovanni Barosi

http://www.w3.org/2001/XMLSchema#string

Giuseppe Prosperini

http://www.w3.org/2001/XMLSchema#string

Josef T Prchal

http://www.w3.org/2001/XMLSchema#string

Leah S Price

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation

European consensus on grading bone marrow fibrosis and assessment of cellularity.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party o

Outcome of transplantation for myelofibrosis.

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

P304

1183-1191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-04-572545

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Judith D Goldberg

John Mascarenhas

Damiano Rondelli

P577

2014-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263397098

http://www.w3.org/2001/XMLSchema#string

P698

24963042

http://www.w3.org/2001/XMLSchema#string

P932

4133490

http://www.w3.org/2001/XMLSchema#string